share_log

Benchmark Maintains Buy on Nutex Health, Lowers Price Target to $1.5

Benzinga ·  Nov 14, 2023 22:16

Benchmark analyst Bill Sutherland maintains Nutex Health (NASDAQ:NUTX) with a Buy and lowers the price target from $2.5 to $1.5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment